{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:40:10Z","timestamp":1739205610336,"version":"3.37.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:p>This decision analytical model study applies restricted mean survival time as a measure of treatment effect in 2 randomized clinical trials assessing disease-modifying treatments vs placebo in patients with progressive multiple sclerosis.<\/jats:p>","DOI":"10.1001\/jamaneurol.2024.4396","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T16:03:41Z","timestamp":1734969821000},"page":"204","source":"Crossref","is-referenced-by-count":0,"title":["Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials"],"prefix":"10.1001","volume":"82","author":[{"given":"Alessio","family":"Signori","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fedriga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Montobbio","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ponzano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Schiavetti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Genoa, Genoa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"nld240013r1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis.","volume":"19","author":"Andersen","year":"2010","journal-title":"Stat Methods Med Res"},{"key":"nld240013r2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"nld240013r3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"10127","key":"nld240013r4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"nld240013r5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"nld240013r6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.7326\/M19-3286","article-title":"Uses and limitations of the restricted mean survival time: illustrative examples from cardiovascular outcomes and mortality trials in type 2 diabetes.","volume":"172","author":"Kloecker","year":"2020","journal-title":"Ann Intern Med"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2828351\/jamaneurology_signori_2024_ld_240013_1738707040.52243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:01:51Z","timestamp":1739203311000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2828351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.4396","relation":{},"ISSN":["2168-6149"],"issn-type":[{"type":"print","value":"2168-6149"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}